PRMT5 inhibitors can inhibit the proliferation, activity and function of CD8 + T cells by up- regulating p53 and weakening Akt pathway, moreover, these inhibitors not only damage tumor cells, but also resist tumor immune response (Strobl et al., 2020). Here, AKT1 is linked to neoplasm.